• Novel Diagnostic System Finds Role of Immune System in Alzheimer’s Disease

    Apr 18 | Diagnostics World | Researchers in Denmark have devised a blood-based diagnostic technique that can detect even trace amounts of an aggregated protein indicative of Alzheimer’s disease before any disease-related changes show up on a PET scan, one of the traditional testing methods. The same technology can be used for developing new therapies by revealing what part of the innate immune system is engaged in the fight. More

  • MRD Futures for Pharma

    Apr 17 | Diagnostics World | Minimal residual disease testing (MRD) has been gaining ground in diagnostics, and a panel took on the topic at the Precision Medicine TriCon late last month. More

  • Age of Opportunity: Artificial Intelligence and the Precision Medicine Future

    Apr 16 | Diagnostics World | At the Precision Med TriConference 2024, Illumina Ventures partner Mara Aspinall sat with Eric Topol, endowed chair and executive VP and professor at Scripps Translational Science Institute, in a fireside chat to discuss precision medicine and artificial intelligence (AI). With three published books and more than 1,200 peer reviewed publications, Topol is one of the industry’s leading minds on digital medicine, and from his perspective, AI needs to be adapted sooner. More

  • New Cortisol Analysis Test Offers Faster, More Accurate Diagnosis

    Apr 11 | Diagnostics World | As the body’s stress hormone, cortisol influences several diseases, from chronic illnesses, such as diabetes and cancer; to mental illnesses, such as depression; to neurological diseases, such as Alzheimer’s disease. Researchers at Aarhus University have discovered a breakthrough method to measure cortisol in an efficient, faster way. More

  • NVIDIA GTC Panel Explores the Role of Generative AI in Medicine

    Apr 09 | Diagnostics World | During the NVIDIA GTC conference held at the San Jose Convention Center and online March 18-21, NVIDIA CEO Jensen Huang highlighted an array of advancements, including new foundation models coming to NVIDIA BioNeMo, a collaboration with Johnson & Johnson MedTech to expand AI’s role in surgical settings, and the launch of over two dozen generative AI microservices to advance areas like digital health, medical technology, and drug discovery. More

  • Time-Of-Day Activity Levels Linked To Amyloid Deposits In The Brain

    Apr 04 | Diagnostics World | A wearable device measuring movement at the wrist can detect clear differences in people who do and don’t have beta-amyloid deposition in their brain. The discovery was enabled by a relatively new statistical technique revealing time-of-day changes in activity levels not captured by standard methods focused on average levels of activity across the day. More

  • EEG Monitoring Concerningly Underutilized In Clinical Trials

    Apr 03 | Diagnostics World | Study sponsors making choices about if, when, and how to include brain monitoring in their clinical studies do not often ground those choices in science or optimize for subject safety and trial de-risking. The key problem is a lack of electroencephalogram (EEG) expertise with no guidance from the Food and Drug Administration (FDA) to mitigate the situation. More

  • Outlook Good for Cancer Diagnostic Industry, Says Panel

    Apr 02 | Diagnostics World | You might be forgiven for calling the tone of a panel on diagnostics held at last week’s Precision Medicine Tri-Con “optimistic”. But you would be corrected: it isn’t optimism, it’s math. More

  • Johns Hopkins University Develops COVID-19 Detection Tool, Fluid Biomarker, Bayer AG Collaborates With Thermo Fisher Scientific, More

    Mar 27 | Diagnostics World | Capstan Therapeutics is advancing CPTX2309, their lead in vivo chimeric antigen receptor T cell (CAR-T) candidate, to early clinical proof-of-concept in autoimmune disorders; Clasp is developing modular T cell engagers tailored to each patient’s immune system that are directed to common oncogenic driver mutations; X-Therma plan to scale global commercial operations and facilitate progression into the clinical stage with FDA Breakthrough Device status, aimed at significantly increasing organ availability for transplantation by overcoming time-sensitive limitations; and more. More

  • Follow the Money: In Vivo CAR-T Candidate Development, Developing Modular TCEs, Increasing Organ Availability, More

    Mar 26 | Diagnostics World | Capstan Therapeutics is advancing CPTX2309, their lead in vivo chimeric antigen receptor T cell (CAR-T) candidate, to early clinical proof-of-concept in autoimmune disorders; Clasp is developing modular T cell engagers tailored to each patient’s immune system that are directed to common oncogenic driver mutations; X-Therma plan to scale global commercial operations and facilitate progression into the clinical stage with FDA Breakthrough Device status, aimed at significantly increasing organ availability for transplantation by overcoming time-sensitive limitations; and more. More
View more articles

 
DXX-Industry-spotlight

merck


Custom Diagnostic Antibody Development & Manufacturing Services

Overcome Process Challenges by outsourcing your custom antibody production to us. How partnering with an antibody production expert can improve your assay, accelerate launch, and maintain your manufacturing.

Learn more